Aprea Therapeutics to Present at October Conferences
Key Highlights
- ➤Oren Gilad to participate in Maxim Growth Summit October 14
- ➤Aprea management to join Regional Biotechnology Conference October 15
- ➤Lead programs APR-1051 and ATRN-119 remain in clinical development
Expert Statements
Oren Gilad, President and CEO of Aprea Therapeutics
“Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit”
DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit, to take place October 12-14 in New York City and the Regional Biotechnology Conference, to take place October 15 in Doylestown, PA.
A webcast of the fireside chat will be available on demand to registered conference attendees. For more information and a complete agenda, please refer to https://www.maximgrp.com/2026-growth-summit.
Get started
Create a free account to read the full story.